Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

ents with heart failure. Results from Nile's Phase Ib and Phase IIa trials are expected to be available in 2008.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated heart failure (ADHF). CD-NP was rationally designed by scientists at the Mayo Clinic's cardio-renal research labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, fu
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... 22, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has accepted for review ... Injection for Subcutaneous Use for the prevention of gout ... Prescription Drug User Fee Act (PDUFA), the goal for ...
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2
(Date:5/25/2013)... York, New York (PRWEB) May 25, 2013 ... who allegedly suffered serious, life-threatening episodes of internal bleeding while ... litigation underway in U.S. District Court, Southern District of Illinois, ... the Court’s website, 818 Pradaxa side effect claims had ... 2013. That’s up from 705 claims reported by the ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On ... to brain cancer research and advocacy, comments on a ... Physics, that shows incorporating cold atmospheric plasma into brain ... , According to a Science Daily ... Physics (MPE), biologists and physicians demonstrated the “synergistic effect ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... CA (PRWEB) May 25, 2013 The Slim ... its effectiveness and results. This is due to the highly ... adhesive patches. Slim weight patch offers an extra 2 months ... loss, fitness goals and get the body you desire faster ... Patch Official Website , With Slim weight patch consumers ...
(Date:5/25/2013)... For college students, few events can ... are turning to prescription stimulants like Adderall to ... on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . , ... students who pick up Adderall, “just to help ... a physical and psychological dependency. While initially they ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... threshold of a new era based on better understanding ... each other. There is great potential for exploiting the ... to develop new drugs that act more specifically without ... nature. , A recent workshop on Biosupramolecular Chemistry ...
... The National Lung Cancer Partnership announced today ... Foundation, the Oncology Nursing Society Foundation and the International ... the mission to increase opportunities for lung cancer researchers ... Lung cancer is the leading cancer killer of men ...
... Study found adults ate worse than children did in ... Members of poor households in which it is consistently ... nutritionally risky diets, Canadian researchers reveal. , The new ... directly translates into poor nutrition. It also suggests that ...
... A new take on pilots, health,workplace injuries connected ... studies to be presented at Preventive Medicine 2008,the ... 2008 in Austin, Texas., Long-Haul Flights May ... investigated if acute stress phenomena associated with,frequent take ...
... Lady Laura Bush,today visited the Maamobi Polyclinic in ... two interventions being implemented by AED to control,malaria., ... with Ghana,s commercial,sector to increase the availability and ... in Ghana and five,other sub-Saharan African countries, and ...
... working together to provide dental offices with exposure, to ... Optimizer(R) and other Sikka Software products that assist, dentists and ... financial performance of their practice. Dental Economics will utilize,Sikka Software,s ... ...
Cached Medicine News:Health News:New understanding of how big molecules bind will lead to better drugs, synthetic organic materials 2Health News:New understanding of how big molecules bind will lead to better drugs, synthetic organic materials 3Health News:National Lung Cancer partnership 2Health News:Poverty Drains Nutrition From Family Diet 2Health News:Poverty Drains Nutrition From Family Diet 3Health News:News Briefs from Preventive Medicine 2008 2Health News:News Briefs from Preventive Medicine 2008 3Health News:First Lady Laura Bush Visits AED/Netmark Malaria-Control Project in Ghana 2Health News:Sikka Software and Dental Economics Announce Alliance 2
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... moderate viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. ... (ul) ... 2~5 Imprecision(%) ... 0.01 Dimensions: ...
... the range from 2ul to 5000ul. Fills ... design prevents inadvertent volume change. Novel hand ... pipette is autoclavable at 121C(250F). To prevent ... Suitable for one-handed operation. Auto or Normal ...
... fully adjustable, air-displacement pipette with a patented ... member of the Pipetman family, sharing many ... precision. We also added a number of ... Eight models cover the full range of ...
Medicine Products: